Paradigm Biocapital Advisors LP

Position in SYRE — Spyre Therapeutics, Inc.

CIK 1855655 NEW YORK, NY

Position in SYRE

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$340,984,270

+$242,259,773 QoQ

Shares Held

3,840,778

+96.2% QoQ

Ownership

4.36%

of shares outstanding

% of Portfolio

7.40%

of 13F equity value

Holder Rank

of 260 holders

Holding Since

Sep 2024

8 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

Paradigm Biocapital Advisors LP holds $4,608,890,546 across 28 Biotechnology names. SYRE ranks #4 (7.4% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	RVMD	Revolution Medicines, Inc.	6,361,323	$1,191,348,571
2	EWTX	Edgewise Therapeutics, Inc.	10,215,455	$415,053,936
3	GMAB	Genmab A/S	13,133,131	$360,767,108
4	SYRE	Spyre Therapeutics, Inc. This page	3,840,778	$340,984,270
5	APGE	Apogee Therapeutics, Inc.	1,576,385	$209,233,581
6	ORKA	Oruka Therapeutics, Inc.	2,144,526	$204,094,539
7	TNGX	Tango Therapeutics, Inc.	6,357,523	$198,736,168
8	BLTE	Belite Bio, Inc	1,232,877	$189,844,564

8 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$340,984,270	3,840,778	+96.2%	Shares	Sole	2026-08-14
2026-03-31	$98,724,497	1,957,266	+33.4%	Shares	Sole	2026-05-15
2025-12-31	$48,067,634	1,467,266	0.0%	Shares	Sole	2026-02-17
2025-09-30	$24,591,378	1,467,266	-21.6%	Shares	Sole	2025-11-14
2025-06-30	$28,000,561	1,870,445	-12.1%	Shares	Sole	2025-08-14
2025-03-31	$34,322,452	2,127,205	+39.3%	Shares	Sole	2025-05-15
2024-12-31	$35,553,332	1,527,205	+20.5%	Shares	Sole	2025-02-14
2024-09-30	$37,279,557	1,267,581	—	Shares	Sole	2024-11-14
No filing history on record for this holder in this stock.